O
Osanni Bio
Therapies to prevent and reverse retinal disease blindness.
About Osanni Bio
Osanni Bio is a development-stage therapeutics platform headquartered in San Francisco, California, reinventing the discovery and development of new medicines. At its center is an innovation engine optimized for discovering new scientific insights, designing novel drug concepts, and efficiently advancing programs to a meaningful proof-of-concept. Its model pairs a centralised research engine with a network of affiliate companies; once a program is de-risked it graduates into its own focused entity to scale. Programs span ophthalmology and cardiology, with an emphasis on capital-efficient drug development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- San Francisco, United States
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 22.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Ophthalmology, Drug Development, Chronic Disease
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2026 | $190M | $760M | Retinal Degeneration Fund · Horowitz Group · Invus Opportunities · Patient Square Capital | ↗ |
Growth signals
Latest recorded traffic for Osanni Bio is 180 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Jerini Ophthalmic Inc.Peptide-based drug development for ophthalmic indications. |
— | Operational | 2 | — | — |
 OtusOphtaLipid-based technology for treating dry eye disease |
Helsinki, Finland | Operational | |||
 CuracleOral therapeutics for age-related intractable vascular diseases |
Seoul, South Korea | Operational | |||
 EclosixSpecialty oral suspension and tablet pharmaceuticals for patients. |
Milton Keynes, United Kingdom | Operational | |||
 EIT PharmaTherapies for serious and life-threatening viral diseases. |
Kirkland, United States | Operational | |||
 CardiaCuresSoftware-linked medicines for personalized cardiovascular dosing. |
— | Operational | |||
 Claveritas PharmaBiotech & Life Sciences |
— | Operational | |||
 Dimicare BiotechPrecision antibiotics for multidrug-resistant pathogens. |
Nice, France | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Patient Square Capital
Retinal Degeneration Fund- HGHorowitz Group
Invus Opportunities
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Osanni Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Osanni Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.